INTRODUCTION Female sexual dysfunction affects up to 43% of women in the United States and hypoactive sexual desire disorder (HSDD) is the most common type; however, we lack treatment options showing improvement for this condition. AIMS To investigate whether acupuncture therapy could improve HSDD. METHODS Premenopausal women with a primary diagnosis of HSDD were included in a single-arm pr...

The objective of the International Society for the Study of Women’s Sexual Health expert consensus panel was to develop a concise, clinically relevant, evidence-based review of the epidemiology, physiology, pathogenesis, diagnosis, and treatment of hypoactive sexual desire disorder (HSDD), a sexual dysfunction affecting approximately 10% of adult women. Etiologic factors include conditions or d...

The Female Sexual Functioning Index (FSFI; Rosen et al., 2000) is a self-report measure of sexual functioning that has been validated on a clinically diagnosed sample of women with female sexual arousal disorder. The present investigation extended the validation of the FSFI to include women with a primary clinical diagnosis of female orgasmic disorder (FOD; n = 71) or hypoactive sexual desire d...

CONTEXT Hypoactive sexual desire disorder (HSDD) is one of the most common sexual problems reported by women, but few studies have been conducted to evaluate treatments for this condition. OBJECTIVE The objective of this study was to evaluate the efficacy and safety of a testosterone patch in surgically menopausal women with HSDD. DESIGN The design was a randomized, double-blind, parallel-g...

BACKGROUND Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with HSDD. MATERIALS AND METHODS This analysis included three 24-week, double-blind,...

INTRODUCTION Recently, there has been much discussion in the literature about how to determine the meaningfulness of results generated from a patient-reported outcome measure. A number of reviews have shown that there are two main approaches: anchor- and distribution-based approaches for determining the minimum important difference (MID) for a new measure. There are issues with calculating an M...

INTRODUCTION Hypoactive Sexual Desire Disorder (HSDD) is characterized by low sexual desire that causes marked distress or interpersonal difficulty. AIM The aim of this study was to assess the efficacy and safety of the 5-HT1A agonist/5-HT2A antagonist flibanserin in premenopausal women with HSDD. METHODS This was a randomized, placebo-controlled trial in which premenopausal women with HSDD...

We are grateful for the opportunity to reply to the Letter to the Editor entitled‘‘Should Sexual Desire and Arousal Disorders in Women Be Merged?’’by DeRogatis, Clayton, Rosen, Sand, and Pyke (2010). Considerable debate has emerged since the publication of our proposed revisions for Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Arousal Disorder (FSAD) for the fifth edition of the D...

Abstract Introduction Low female sexual desire (HSDD) is one of the most common complaints in women. As a result, many women suffer from dissatisfaction and related distress, which often negatively interferes with their quality life. Little known about underlying biological mechanism low desire, but it conceivable that functions are result an interaction between biological, psychological, relat...

In recent decades, women are increasingly contact the doctors with problems of hypoactive sexual desire disorders (HSDD). Female libido is considered as one important indicators quality life, health. Therapy HSDD difficult due to insufficient knowledge by both complex, multiple pathogenetic mechanisms reduction and modern therapeutic approaches. this article, female from point view biopsychosoc...